Evidence map›Paper›PMID 20074925›Full record

ReviewCurrent opinion in immunology2010

Alphabeta versus gammadelta lineage choice at the first TCR-controlled checkpoint.

Taras Kreslavsky, Michael Gleimer, Harald von Boehmer

Abstract readReview
In one paragraph

Review in Current opinion in immunology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 39 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. A Beginner's Guide to T Cell Development.Methods in molecular biology (Clifton, N.J.) · 2023
    Review
  7. RNA mProceedings of the National Academy of Sciences of the United States of America · 2022
    Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Design principles of adaptive immune systems.Nature reviews. Immunology · 2011
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Taras KreslavskyLaboratory of Lymphocyte Biology, Cancer Immunology & AIDS, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Michael Gleimer
Harald von Boehmer
Dana-Farber Cancer Institute · US

Funding

pTa-controlled reporter to identify lymphoid precursorR01AI051378 · NIAID · DANA-FARBER CANCER INSTITUTE · PI VON BOEHMER, HARALD · 2003 to 2012
$4.1M
ROLE OF THE PRE-T CELL RECEPTOR IN LINEAGE COMMITMENTR01AI045846 · NIAID · DANA-FARBER CANCER INSTITUTE · PI VON BOEHMER, HARALD · 2000 to 2010
$4.0M
NIAID NIH HHS R01 AI045846NIAID NIH HHS R01 AI051378PHS HHS R01 A145846PHS HHS R01 A151378
6 · The paper itself

Abstract

Alphabeta and gammadelta T cells develop in the thymus from a common precursor. Although lineages initially were defined by the type of TCR they express, it soon became clear that the TCR type per se does not play a deterministic role in the lineage decision, since in various transgenic and knockout models, as well as in a small fraction of cells in wt mice, the TCRgammadelta can drive the differentiation of alphabeta lineage cells and the TCRalphabeta can drive differentiation of gammadelta lineage cells. Thus until recently it was unclear what determines lineage choice and at which stage the two lineages diverge. Recent observations suggest that TCR signal strength determines lineage fate and that lineage choice is made at or shortly after the first TCR-controlled checkpoint. While it is clear that the decision between alphabeta and gammadelta lineages is made at the first TCR-controlled checkpoint and the alphabeta sublineages split off later, it is less clear whether gammadelta sublineages divert already at the first TCR-controlled checkpoint or later. Recent experiments support the former view.

Indexed as

LymphopoiesisAnimalsCell LineageHumansPrecursor Cells, T-LymphoidReceptors, Antigen, T-Cell, alpha-betaReceptors, Antigen, T-Cell, gamma-deltaReceptors, NotchSignal TransductionT-LymphocytesReceptors, Antigen, T-Cell, alpha-betaReceptors, Antigen, T-Cell, gamma-deltaReceptors, Notch

Identifiers

PMID20074925
PMCPMC2861550
OpenAlexW1996811838

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.